Guido Marcucci
Division of Hematology-Oncology
Department of Medicine
and the Comprehensive Cancer Center
Ohio State University
USA
Name/email consistency: high
- Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Marcucci, G., Mrózek, K., Bloomfield, C.D. Curr. Opin. Hematol. (2005)
- Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. Marcucci, G., Stock, W., Dai, G., Klisovic, R.B., Liu, S., Klisovic, M.I., Blum, W., Kefauver, C., Sher, D.A., Green, M., Moran, M., Maharry, K., Novick, S., Bloomfield, C.D., Zwiebel, J.A., Larson, R.A., Grever, M.R., Chan, K.K., Byrd, J.C. J. Clin. Oncol. (2005)
- Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. Marcucci, G., Mrózek, K., Ruppert, A.S., Maharry, K., Kolitz, J.E., Moore, J.O., Mayer, R.J., Pettenati, M.J., Powell, B.L., Edwards, C.G., Sterling, L.J., Vardiman, J.W., Schiffer, C.A., Carroll, A.J., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2005)
- Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. Marcucci, G., Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrózek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O., Perrotti, D., Caligiuri, M.A., Carroll, A.J., Larson, R.A., de la Chapelle, A., Bloomfield, C.D. J. Clin. Oncol. (2005)
- Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. Marcucci, G., Mrózek, K., Ruppert, A.S., Archer, K.J., Pettenati, M.J., Heerema, N.A., Carroll, A.J., Koduru, P.R., Kolitz, J.E., Sterling, L.J., Edwards, C.G., Anastasi, J., Larson, R.A., Bloomfield, C.D. J. Clin. Oncol. (2004)
- Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Marcucci, G., Byrd, J.C., Dai, G., Klisovic, M.I., Kourlas, P.J., Young, D.C., Cataland, S.R., Fisher, D.B., Lucas, D., Chan, K.K., Porcu, P., Lin, Z.P., Farag, S.F., Frankel, S.R., Zwiebel, J.A., Kraut, E.H., Balcerzak, S.P., Bloomfield, C.D., Grever, M.R., Caligiuri, M.A. Blood (2003)
- Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations. Clin. Cancer Res., 9: 1333-1337, 2003. Marcucci, G., Perrotti, D., Caligiuri, M.A. Clin. Cancer Res. (2003)
- Core binding factor (CBF) acute myeloid leukemia: is molecular monitoring by RT-PCR useful clinically?. Marcucci, G., Caligiuri, M.A., Bloomfield, C.D. Eur. J. Haematol. (2003)
- Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Marcucci, G., Caligiuri, M.A., Bloomfield, C.D. Cancer Invest. (2000)